Recombinant, nonglycosylated human insulin-like growth factor-binding protein-3 (IGFBP-3) is degraded preferentially after administration to type II diabetics, resulting in increased endogenous glycosylated IGFBP-3

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 12, 2005, Pages 6561-6568

  Clemmons, D R ^a   Sleevi, M ^b   Busby Jr , W H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Insmed Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; IN VITRO STUDY; INCUBATION TIME; MOLECULAR STABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG STABILITY; GLYCOSYLATION; HUMANS; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 28744440276     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1389     Document Type: Article

References (38)

1. Adams S, Moore J, Chu S, Bagi C, DeLeon L, Lui C, Schmidt D, Sommer A 1995 Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey. Prog Growth Factor Res 6:347-356
2. Herndon DN, Ramzy PI, DebRoy MA, Zheng M, Ferrando AA, Chinkes DL, Barret JP, Wolfe RR, Wolf SE 1999 Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 229:713-722
3. Debroy MA, Wolf SE, Zhang XJ, Chinkes DL, Ferrando AA, Wolfe RR, Herndon DN 1999 Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma Injury Infect Crit Care 47:904-911
4. Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, Vandershueren O, Geusens P 2002 Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 87:1593-1599
5. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J 2000 The combination of insulin-like growth factor I and insulin-like growth factor binding protein-3 reduces insulin requirements in insulin dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85:1518-1524
6. Davenport ML, D'Ercole AJ, Underwood LE 1990 Effects of maternal fasting on fetal growth serum insulin like growth factors (IGF's) and tissue IGF messenger ribonucleic acids. Endocrinology 126:2062-2067
7. Guidice LC, Farrell EM, Pham H, Lamson FG, Rosenfeld RG 1990 Insulin like growth factor binding proteins in maternal serum throughout gestation and in the puerperium. J Clin Endocrinol Metab 71:806-816
8. Hossenlopp P, Segovia B, Lassare C, Roghani M, Bredon M, Binoux M 1990 Enzymatic evidence of degradation of insulin-like growth factor binding protein in 150 k complex during pregnancy. J Clin Endocrinol Metab 71:797-805
9. Davenport ML, Isley WL, Pucilowska J, Penberton B, Lyman B, Underwood LE, Clemmons DR 1992 Insulin-like growth factor binding protein-3 proteolysis is induced following elective surgery. J Clin Endocrinol Metab 130:2505-2512
10. Cwyfan-Hughes S, Cotterill AM, Molloy A 1992 Induction of specific proteases for insulin-like growth factor binding protein following major heart surgery. J Endocrinol 135:135-145
11. Frost RA, Nachman SA, Lang CH, Gelato MC 1996 Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children who fail to thrive. J Clin Endocrinol Metab 81:2957-2962
12. Abribat T, Nedelec B, Jobin N, Garrel DR 2000 Decreased serum insulin-like growth factor-I in burn patients: relationship with serum insulin-like growth factor binding protein-3 proteolysis and the influence of lipid composition in nutritional support. Crit Care Med 28:2366-2372
13. Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA 1995 Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 80:2282-2288
14. Bang P, Brismar K, Rosenfeld RG 1994 Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29 kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130-150 kDa ternary complex. J Clin Endocrinol Metab 78:1119-1127
15. Maile LA, Xu S, Cwyfan-Hughes SC, Fernihough JK, Pell JM, Holly JM 1998 Active and inhibitory components of the insulin-like growth factor binding protein-3 protease system in adult serum, interstitial, and synovial fluid. Endocrinology 139:4772-4781
16. Skjarbaek C, Frystyk J, Orskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, Moller N, Flyvbjerg A 1998 Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor binding protein-3 proteolysis. J Clin Endocrinol Metab 83:2445-2449
17. Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G 2005 Rh/IGF-I/IGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. GH IGF-I Res 15:265-274
18. Bagi CM, DeLeon E, Brommage R, Rosen D, Sommer A 1995 Treatment of ovariectomized rats with the complex of rhIGF-I/IGFBP-3 increases cortical and cancellous bone mass and improves structure in the femoral neck. Cal Tissue Inter 57:40-46
19. Smith WJ, Nam TJ, Underwood LE, Busby WJ, Celniker A, Clemmons DR 1993 Use of insulin-like growth factor binding protein 2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 77:1294-1299
20. Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V 1998 Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 58:353-360
21. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H 1999 Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 15:314-322
22. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA 1995 Effect of insulin on the insulin-like growth factor system in children with new onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 80:1312-1317
23. Lassarre C, Binoux M 2001 Measurement of intact insulin-like growth factor-binding protein-3 in human plasma using a ligand immunofunctional assay. J Clin Endocrinol Metab 86:1260-1266
24. Diamandi A, Mistry J, Krishna RG Khosravi J 2000 Immunoassay of insulin-like growth factor-binding protein-3 (IGFBP-3): new means to quantifying IGFBP-3 proteolysis J Clin Endocrinol Metab 85:2327-2333
25. Gravholt CH, Frystyk J, Flyvbjerg A, Orskov H, Christiansen JS 2001 Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am J Physiol 280:E308-E314
26. Lassarre C, Binoux M 1994 Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 134:1254-1262
27. Blat C, Villaudy J, Binoux M 1994 In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93:2286-2290
28. Gargosky SE, Pham H, Wilson KF, Liu F, Guidice LC, Rosenfeld RG 1992 Measurement and characterization of insulin-like growth factor binding protein-3 in human biologic fluids discrepancy between radioimmunoassays and ligand blotting. Endocrinology 131:3051-3060
29. Akinci A, Copeland KC, Garmon A, Clemmons DR 2000 Insulin-like growth factor binding proteins (IGFBP-1, 2, 3) in serum and urine and IGFBP-2 protease activity from patients with IDDM. Metabolism 49:626-633
30. Spagnoli A, Gargosky SE, Spadoni GL, MacGillivray M, Oh Y, Boscherini G, Rosenfeld RG 1995 Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from health children and growth hormone (GH)-deficient patients: relationship with GH therapy. J Clin Endocrinol Metab 80:3668-3676
31. Binoux M, Lalou C, Lassarre C, Hossenlopp P 1993 Limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3): a physiological mechanism in the regulation of IGF bioavailability. Adv Exp Med Biol 343:293-300
32. Baxter RC, Skriver L 1993 Altered ligand specificity of proteolysed insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 196:1267-1273
33. Lassarre C, Duron F, Binoux M 2001 Use of the ligand immunofunctional assay for human insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and IGF-I bioavailability in health adults, GH-deficient and acromegalic patients, and diabetes. J Clin Endocrinol Metab 86:1942-1952
34. Booth BA, Boes M, Bar RS 1996 IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding and structure of fragments. Am J Physiol 271:E465-E470
35. Koistinen H, Paju A, Koinstinen R, Finne P, Lovgren J, Wu P, Seppala M, Stenman UH 2002 Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50:112-118
36. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, Moreau T 2001 Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268:2960-2988
37. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ 2000 ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protine-3. J Biol Chem 275:18574-18580
38. Lalou C, Silve C, Rosato R, Binoux M 1994 Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135:2318-2326